Cargando…

Il-6 is non-essential to murine CD19 CAR efficacy, but can mediate acute GVHD following allogeneic BMT with CAR T cell infusion

Detalles Bibliográficos
Autores principales:	Jacoby, Elad, Qin, Haiying, Kochenderfer, James, Yang, Yinmeng, Chien, Chris, Fry, Terry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649356/ http://dx.doi.org/10.1186/2051-1426-3-S2-P226

Ejemplares similares

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects
por: Patterson, Michael T., et al.
Publicado: (2023)

Anterior chamber infiltration of CAR T-cells
por: Jacoby, Elad, et al.
Publicado: (2021)

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
por: Jacoby, Elad, et al.
Publicado: (2016)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19
por: Lian, Yu, et al.
Publicado: (2023)

Murine Models of Acute Leukemia: Important Tools in Current Pediatric Leukemia Research
por: Jacoby, Elad, et al.
Publicado: (2014)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Recent Advances in Allogeneic CAR-T Cells
por: Kim, Dong Wook, et al.
Publicado: (2020)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

Allogeneic BMT in ATL: whom to transplant and which modality to use
por: Kannagi, Mari
Publicado: (2014)

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes
por: Faruqi, Aiman J., et al.
Publicado: (2022)

Impact of cryopreservation on CAR T production and clinical response
por: Brezinger-Dayan, Karin, et al.
Publicado: (2022)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Long-term outcomes following CAR T cell therapy: what we know so far
por: Cappell, Kathryn M., et al.
Publicado: (2023)

Mediport use as an acceptable standard for CAR T cell infusion
por: Eylon, Maya, et al.
Publicado: (2023)

IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020)

Intrathecal CAR-NK cells infusion for isolated CNS relapse after allogeneic stem cell transplantation: case report
por: Yuan, Jing, et al.
Publicado: (2023)

Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
por: Holland, Elizabeth M, et al.
Publicado: (2022)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products
por: Shao, Lipei, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT)
por: Dyer, Gemma, et al.
Publicado: (2016)

Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology
por: Lontos, Konstantinos, et al.
Publicado: (2022)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression
por: Lanitis, Evripidis, et al.
Publicado: (2020)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
por: Valton, Julien, et al.
Publicado: (2015)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
por: Wu, Xiaolong, et al.
Publicado: (2022)

Umbilical cord blood: A promising source for allogeneic CAR-T cells
por: Liu, Dian-Dian, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
por: Katz, Steven, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3ek3vo36pdn5at7ai7rqq9pl3u